Orbimed Advisors Increased Its Newlink Genetics (NLNK) Stake; As Enterprise Prods Partners LP (EPD) Market Value Declined, Green Square Capital Has Decreased Holding

December 8, 2017 - By Linda Rogers

Green Square Capital Llc decreased its stake in Enterprise Prods Partners LP (EPD) by 16.64% based on its latest 2017Q2 regulatory filing with the SEC. Green Square Capital Llc sold 83,909 shares as the company’s stock declined 6.06% while stock markets rallied. The hedge fund held 420,367 shares of the natural gas distribution company at the end of 2017Q2, valued at $11.38 million, down from 504,276 at the end of the previous reported quarter. Green Square Capital Llc who had been investing in Enterprise Prods Partners LP for a number of months, seems to be less bullish one the $53.36 billion market cap company. The stock increased 1.48% or $0.36 during the last trading session, reaching $24.69. About 4.86 million shares traded. Enterprise Products Partners L.P. (NYSE:EPD) has declined 0.18% since December 8, 2016 and is downtrending. It has underperformed by 16.88% the S&P500.

Samuel Isaly increased its stake in Newlink Genetics Corp (NLNK) by 823% based on its latest 2017Q2 regulatory filing with the SEC. Orbimed Advisors Llc bought 1.65 million shares as the company’s stock declined 3.21% while stock markets rallied. The hedge fund run by Samuel Isaly held 1.85M shares of the major pharmaceuticals company at the end of 2017Q2, valued at $13.57M, up from 200,000 at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Newlink Genetics Corp for a number of months, seems to be bullish on the $298.10 million market cap company. The stock increased 1.90% or $0.15 during the last trading session, reaching $8.04. About 1.13 million shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has risen 49.90% since December 8, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.

Orbimed Advisors Llc, which manages about $6.70B and $9.54 billion US Long portfolio, decreased its stake in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) by 142,698 shares to 2.03 million shares, valued at $261.16M in 2017Q2, according to the filing. It also reduced its holding in Xencor Inc (NASDAQ:XNCR) by 92,993 shares in the quarter, leaving it with 747,244 shares, and cut its stake in Allergan Plc.

Among 6 analysts covering NewLink Genetics (NASDAQ:NLNK), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NewLink Genetics has $3200 highest and $7.0 lowest target. $22.33’s average target is 177.74% above currents $8.04 stock price. NewLink Genetics had 15 analyst reports since March 23, 2016 according to SRatingsIntel. SunTrust upgraded the stock to “Buy” rating in Thursday, March 30 report. As per Friday, November 3, the company rating was maintained by Jefferies. The rating was maintained by Jefferies on Thursday, August 24 with “Hold”. The rating was maintained by Robert W. Baird with “Buy” on Friday, October 13. The stock has “Outperform” rating by Robert W. Baird on Wednesday, March 23. As per Friday, September 8, the company rating was upgraded by Robert W. Baird. The firm earned “Buy” rating on Thursday, August 31 by Stifel Nicolaus. The stock has “Buy” rating by Stifel Nicolaus on Monday, July 10. The rating was downgraded by SunTrust to “Neutral” on Wednesday, May 11. The rating was upgraded by Jefferies to “Buy” on Friday, September 8.

More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Fool.com which released: “Here’s Why NewLink Genetics Is Vaulting 45% Higher Today” on September 07, 2017, also Globenewswire.com with their article: “NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study …” published on November 20, 2017, Globenewswire.com published: “NewLink Genetics to Participate in Upcoming Investor Conference” on November 27, 2017. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Seekingalpha.com and their article: “NewLink Genetics Won’t Go Down Without A Fight” published on September 11, 2017 as well as Fool.com‘s news article titled: “The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September” with publication date: October 09, 2017.

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.19, from 1.13 in 2017Q1. It worsened, as 23 investors sold NLNK shares while 29 reduced holdings. 17 funds opened positions while 32 raised stakes. 15.81 million shares or 10.39% more from 14.32 million shares in 2017Q1 were reported. North Star Management holds 0% or 1,170 shares in its portfolio. Da Davidson & Company holds 40 shares or 0% of its portfolio. Jpmorgan Chase & invested in 555 shares. Vanguard Grp holds 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK) for 926,750 shares. Ubs Asset Management Americas Incorporated accumulated 0% or 12,330 shares. Panagora Asset owns 1,675 shares or 0% of their US portfolio. Swiss National Bank & Trust reported 0% stake. 6,096 were accumulated by Retail Bank Of America Corporation De. Creative Planning has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Great West Life Assurance Co Can stated it has 2,048 shares or 0% of all its holdings. Tiaa Cref Mngmt Ltd Liability invested in 93,963 shares. Wells Fargo Mn owns 0% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 165,791 shares. 29,369 were accumulated by Hbk Invs Ltd Partnership. Proshare Ltd Liability Corp reported 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK). Rhumbline Advisers invested 0% of its portfolio in NewLink Genetics Corporation (NASDAQ:NLNK).

More notable recent Enterprise Products Partners L.P. (NYSE:EPD) news were published by: Seekingalpha.com which released: “Buy Enterprise Products Partners” on November 16, 2017, also Nasdaq.com with their article: “Enterprise Products (EPD) Plans to Reconstruct NGL Pipelines” published on December 07, 2017, Seekingalpha.com published: “Enterprise Products Partners: Keep The Faith” on November 10, 2017. More interesting news about Enterprise Products Partners L.P. (NYSE:EPD) were released by: Seekingalpha.com and their article: “Enterprise Products Partners LP (EPD) Present at Wells Fargo Securities …” published on December 06, 2017 as well as Fool.com‘s news article titled: “Better Buy: Enterprise Products Partners LP vs. Kinder Morgan, Inc.” with publication date: December 06, 2017.

Investors sentiment decreased to 0.99 in 2017 Q2. Its down 0.06, from 1.05 in 2017Q1. It fall, as 54 investors sold EPD shares while 250 reduced holdings. 58 funds opened positions while 244 raised stakes. 780.09 million shares or 1.82% more from 766.14 million shares in 2017Q1 were reported. Comerica National Bank has 59,604 shares. Bourgeon Cap Management Lc invested in 104,875 shares. Fiduciary Services Of The Southwest Tx owns 380,199 shares or 3.17% of their US portfolio. 5,879 are held by Howe & Rusling Inc. Jefferies Grp Inc Ltd reported 23,502 shares. Weiss Multi reported 0.53% stake. Artemis Invest Mngmt Llp reported 32,474 shares. 10 stated it has 0.75% in Enterprise Products Partners L.P. (NYSE:EPD). Riggs Asset Managment accumulated 2.2% or 181,352 shares. Nbw Cap Ltd Limited Liability Company stated it has 0.08% in Enterprise Products Partners L.P. (NYSE:EPD). 111,373 are held by Keybank National Association Oh. Glenmede Na accumulated 478,419 shares. Moreover, Cornerstone Advisors Inc has 0% invested in Enterprise Products Partners L.P. (NYSE:EPD). Palisade Asset Mgmt Ltd Llc has 0.05% invested in Enterprise Products Partners L.P. (NYSE:EPD). Parkwood Ltd Liability Corporation has invested 0.23% of its portfolio in Enterprise Products Partners L.P. (NYSE:EPD).

Analysts await Enterprise Products Partners L.P. (NYSE:EPD) to report earnings on January, 29. They expect $0.35 EPS, up 12.90% or $0.04 from last year’s $0.31 per share. EPD’s profit will be $756.38 million for 17.64 P/E if the $0.35 EPS becomes a reality. After $0.30 actual EPS reported by Enterprise Products Partners L.P. for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Among 24 analysts covering Enterprise Products Partners LP (NYSE:EPD), 23 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Enterprise Products Partners LP has $38 highest and $29 lowest target. $32.20’s average target is 30.42% above currents $24.69 stock price. Enterprise Products Partners LP had 47 analyst reports since July 23, 2015 according to SRatingsIntel. On Monday, June 5 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Enterprise Products Partners L.P. (NYSE:EPD) earned “Overweight” rating by Piper Jaffray on Friday, April 1. The stock has “Buy” rating by Deutsche Bank on Wednesday, November 18. The rating was upgraded by Morgan Stanley on Thursday, June 15 to “Overweight”. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Thursday, August 18. The firm has “Buy” rating given on Tuesday, August 15 by BMO Capital Markets. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, October 12 report. Credit Suisse downgraded Enterprise Products Partners L.P. (NYSE:EPD) rating on Thursday, March 17. Credit Suisse has “Neutral” rating and $30 target. The company was maintained on Thursday, August 3 by Jefferies. As per Wednesday, November 16, the company rating was initiated by Ladenburg Thalmann.

Green Square Capital Llc, which manages about $1.82B and $563.87M US Long portfolio, upped its stake in Target Corp Com (NYSE:TGT) by 33,779 shares to 106,393 shares, valued at $5.56 million in 2017Q2, according to the filing. It also increased its holding in Qualcomm Inc (NASDAQ:QCOM) by 9,699 shares in the quarter, for a total of 111,821 shares, and has risen its stake in Schwab Etfs (SCHB).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: